The prostate cancer therapy market will soar. Here are the companies that could benefit.
With the number of new prostate cancer cases rising in the US since 2014 according to the CDC, the market for therapies to treat the cancer is increasing.
The wholesale acquisition price is $42,500 per injection and patients can receive a maximum of six shots.
As a later-stage therapy, Novartis (.
But if it is eventually approved in earlier lines of treatment, the exec predicted revenue could be three to four times that range.
Alpmy), while Orgovyx, an androgen deprivation therapy, was developed with Myovant Sciences (.
In Q2, Erleada had worldwide sales of $450M, while Zytiga brought in $505M.
In the pipeline, J&J is examining Erleada in phase 3 for high risk prostate cancer.
According to Amgen, the BiTEs “are designed to form a bridge between cancer cells and cytotoxic T cells—white blood cells that can destroy other cells that pose a threat.”.
More Web Stories